Visualized analysis on researches of posterior reversible encephalopathy syndrome based on Web of Science database

doi:10.3760/cma.j.issn.1007-1245.2024.05.003

Abstract

Abstract:

Objective　To investigate the status, hotspots, and frontiers of global scientific researches on posterior reversible encephalopathy syndrome (PRES) through the visualized atlas. Methods　The literatures on PRES were searched from the Web of Science database from its establishment to December 31, 2022 on May 12, 2023. The visualized software was used to perform the atlas analysis. Results　A total of 1 778 articles were retrieved. The article number increased year by year. The keyword clustering found 11 clusters, involving hypertensive encephalopathy, tacrolimus, magnetic resonance imaging, etc. The keyword burst analysis indicated that the main research frontiers were pathophysiology, risk factors, COVID-19 infection, cytokines, etc. Conclusions　It is believed that the incidence of PRES is related to damage of blood-brain barrier. In recent years, endothelial injury and brain tissue hypoperfusion mediated by vasoconstrictors after COVID-19 infection may induce PRES.

Key words:

Reversible , posterior , leukoencephalopathy , syndrome, Posterior reversible encephalopathy syndrome, Web of Science, Visualized analysis

摘要：

目的　通过可视化图谱探讨可逆性后部脑病综合征（posterior reversible encephalopathy syndrome，PRES）研究现状、热点及前沿动态。方法　检索Web of Science数据库中关于PRES文献，时间范围为从数据库建立至2022年12月31日，检索日期为2023年5月12日。采用可视化软件进行图谱分析。结果　检索1 778篇文献，从累计年发文量来看，文献数量不断增加；对关键词进行聚类分析，得到11个聚类群，涉及高血压脑病、他克莫司、磁共振成像等；关键词突现提示病理生理学、危险因素、新型冠状病毒感染、细胞因子等为前沿热点。结论 PRES发病与血脑屏障破坏有关。近年来，新型冠状病毒感染后缩血管物质所介导的内皮损伤和脑组织低灌注可引发PRES。

关键词:

可逆性后部脑白质变性, 可逆性后部脑病综合征, Web of Science, 可视化分析

Xiang Lingli, Zhang Kai, Shao Yong.

Visualized analysis on researches of posterior reversible encephalopathy syndrome based on Web of Science database [J]. International Medicine and Health Guidance News, 2024, 30(5): 713-720.

相玲丽张凯邵勇.

基于Web of Science数据库可逆性后部脑病综合征研究的可视化分析 [J]. 国际医药卫生导报, 2024, 30(5): 713-720.

References

[1] Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome[J].N Engl J Med,1996,334(8):494-500.DOI:10.1056/NEJM199602223340803.
[2] Casey SO, Sampaio RC, Michel E, et al. Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions[J].AJNR Am J Neuroradiol,2000,21(7):1199-1206.
[3] Shekhar S, Liu R, Travis OK, et al. Cerebral autoregulation in hypertension and ischemic stroke: a mini review[J].J Pharm Sci Exp Pharmacol,2017,2017(1):21-27.
[4] Tseng YJ, Chen CN, Hong RL, et al. Posterior reversible encephalopathy syndrome after lenvatinib therapy in a patient with olfactory neuroblastoma[J].Brain Sci,2022,13(1):33.DOI:10.3390/brainsci13010033.
[5] Irvin W, MacDonald G, Smith JK, et al. Dexamethasone-i nduced posterior reversible encephalopathy syndrome[J].J Clin Oncol,2007,25(17):2484-2486.DOI:10.1200/JCO.2007.10.9991.
[6] Hawkes MA, Hajeb M, Rabinstein AA. Perfusion deficits in patients with posterior reversible encephalopathy syndrome: a retrospective, two-center Study[J].Neurocrit Care,2023,38(3):726-732.DOI:10.1007/s12028-022- 01642-9.
[7] Papachristou E, Papadimitropoulos A, Kotsantis P, et al. Cyclosporine induces endothelin-1 mRNA synthesis and nitric oxide production in human proximal tubular epithelial cell cultures[J].Ren Fail,2009,31(5):372-376.DOI:10.1080/08860220902882022.
[8] Nasser SA, Elmallah AI, Sabra R, et al. Blockade of endothelin ET(A), but not thromboxane, receptors offsets the cyclosporine-evoked hypertension and interrelated baroreflex and vascular dysfunctions[J].Eur J Pharmacol,2014,727:52-59. DOI:10.1016/j.ejphar.2014.01.034.
[9] 厉海娜,曲方. 非外伤性皮质凸面蛛网膜下腔出血237例汇集分析[J]. 中国临床神经科学,2014(5):545-551.DOI:10.3969/j.issn.1008-0678.2014.05.011.
[10] Calviere L, Raposo N, Cuvinciuc V, et al. Patterns of convexal subarachnoid haemorrhage: clinical, radiological and outcome differences between cerebral amyloid angiopathy and other causes[J].J Neurol,2018,265(1):204-210.DOI:10.1007/s00415-017-8693-7.
[11] Jeanneret V, Jillella DV, Rangaraju S, et al. PRES and RCVS: two distinct entities or a spectrum of the same disease?[J].J Stroke Cerebrovasc Dis,2022,31(6):106472.DOI:10.1016/j.jstrokecerebrovasdis.2022.106472.
[12] Wang Q, Huang B, Shen G, et al. Blood-brain barrier disruption as a potential target for therapy in posterior reversible encephalopathy syndrome: evidence from multimodal MRI in rats[J].Front Neurol,2019,10:1211.DOI:10.3389/fneur.2019.01211.
[13] Lee SY, Kim SH, Lee SH, et al. Serial MR spectroscopy in relapsing reversible posterior leukoencephalopathy syndrome[J].Neurologist,2009,15(6):338-341.DOI:10.1097/NRL.0b013e3181914af6.
[14] Liman TG, Bohner G, Heuschmann PU, et al. The clinical and radiological spectrum of posterior reversible encephalopathy syndrome: the retrospective Berlin PRES study[J].J Neurol,2012,259(1):155-164.DOI:10.1007/s00415-011-6152-4.
[15] Bartynski WS, Boardman JF. Catheter angiography, MR angiography, and MR perfusion in posterior reversible encephalopathy syndrome[J].AJNR Am J Neuroradiol,2008,29(3):447-455.DOI:10.3174/ajnr.A0839.
[16] McKinney AM, Short J, Truwit CL, et al. Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings[J].AJR Am J Roentgenol,2007,189(4):904-912.DOI:10.2214/AJR.07.2024.
[17] 王朋,王琳,张文迪. 3.0TMRI、MSCT诊断鉴别可逆性后部白质脑病综合征的价值[J]. 影像研究与医学应用,2021,5(19):168-169.DOI:10.3969/j.issn.2096-3807. 2021.19.081.
[18] Miskatul mustafa mishu,孔祥.可逆性后部脑病综合征与妊娠关系的研究进展[J].国际医药卫生导报,2019,25(13):2018-2020.DOI:10.3760/cma.j.issn. 1007-1245. 2019.13.001.
[19] Li K, Yang Y, Guo D, et al. Clinical and MRI features of posterior reversible encephalopathy syndrome with atypical regions: a descriptive study with a large sample size[J].Front Neurol,2020,11:194.DOI:10.3389/fneur.2020.00194.
[20] Imai H, Okuno N, Ishihara S, et al. Reversible posterior leukoencephalopathy syndrome after carboplatin and paclitaxel regimen for lung cancer[J].Intern Med,2012,51(8):911-915.DOI:10.2169/internalmedicine.51.6723.
[21] Tetsuka S, Ogawa T. Posterior reversible encephalopathy syndrome: a review with emphasis on neuroimaging characteristics[J].J Neurol Sci,2019,404:72-79.DOI:10.1016/j.jns.2019.07.018.
[22] Ho CH, Lo CP, Tu MC. Bortezomib-induced posterior reversible encephalopathy syndrome: clinical and imaging features[J].Intern Med,2014,53(16):1853-1857.DOI:10.2169/internalmedicine.53.2383.
[23] Politi LS, Salsano E, Grimaldi M. Magnetic resonance imaging alteration of the brain in a patient with coronavirus disease 2019 (COVID-19) and anosmia[J].JAMA Neurol,2020,77(8):1028-1029.DOI:10.1001/jamaneurol.2020.2125.
[24] Doo FX, Kassim G, Lefton DR, et al. Rare presentations of COVID-19: PRES-like leukoencephalopathy and carotid thrombosis[J].Clin Imaging,2021,69:94-101.DOI:10.1016/j.clinimag.2020.07.007.
[25] Poyiadji N, Shahin G, Noujaim D, et al. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: imaging features[J].Radiology,2020,296(2):E119-E120.DOI:10.1148/radiol.2020201187.
[26] Rogg J, Baker A, Tung G. Posterior reversible encephalopathy syndrome (PRES): another imaging manifestation of COVID-19[J].Interdiscip Neurosurg,2020,22:100808.DOI:10.1016/j.inat.2020.100808.
[27] Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema[J].AJNR Am J Neuroradiol,2008,29(6):1043-1049.DOI:10.3174/ajnr.A0929.
[28] Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `cytokine storm' in COVID-19[J].J Infect,2020,80(6):607-613.DOI:10.1016/j.jinf.2020.03.037.
[29] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J].Lancet,2020,395(10223):497-506.DOI:10.1016/S0140-6736(20)30183-5.